- The document provides information on ReNeual, a company developing a portable dialysis machine called DIALO-mini. - It outlines ReNeual's team members and scientific advisors, as well as its mission to lead renal failure treatment through developing DIALO-mini. - The document then provides details on DIALO-mini's design, development process, target specifications, growth strategy, and financial projections.

2. Briyana C.
Sizer
COO
Faisal
Almansour
CSO
Chia-Yi
Liu
CMO
Feibai
Wang
CEO
OUR TEAM

3. SCIENCE ADVISORY BOARD
Dr. Victor Gura M.D
Kidney Specialist
Cedar-Sinai Medical Center
Los Angeles, CA
Dr. Amanda Buck Ph.D
Instructor in Radiology
School of Engineering,
Vanderbilt University
Nashville, TN

4. New Mexico

5. OUR MISSION STATEMENT
Leading the field of renal failure treatment,
based on developing a major product,
DIALO-mini, which is a small portable dialysis machine.

7. DIALO-mini
By ReNeual

8. DIALO-mini
DIALO-mini
Server DIALO-mini
Trained
medical
staff

9. Faisal Almansour CSO

10. Concept Design & Product Development Plan
Planning
Concept
Development
System-
Level
Design
Testing &
Refinemen
t
Validation
&
Approval
Design
Design
Design
Design
Test
Test
Test
Test
Mission
Approval
Concept
Review
Syste
m
Revie
w
Production
Approval
Project
Review
• Initiate product
Platform &
architecture.
• Value new
Technologies.
• Explore
feasibility of
product
concepts.
• Begin industrial
design
concepts.
• Build & test
experimental
prototype
• Develop product
architecture.
• Develop major
sub-systems
and interfaces.
• Adjust industrial
design.
• Initiate
component
engineering.
• Define part
geometry.
• Choose
material.
• Set tolerance.
• Complete
industrial
design control
documentation
• Evaluate early
production
output• Our company takes a very serious approach in understanding customer needs.
• Our medical device pathway start with a collection of ideas that goes through a very
precise regulatory processes to insure product quality, safety, and efficacy.
• Our Marketing, Design, and Manufacturing team play simultaneously to produce a
high quality product.
• Evaluate
overall
performance,
reliability, and
durability.
• Consider
environmental
impact.
• Implement
design
changes.
• Apply &
Obtain
regulatory
approvals.
Class II
2020
PMA
1-3 Years
Classify
Device
Premarket
Submission
Approval CGMP

11. Mobility Ergonomic
Concept Design & Product Development
Target Specification

12. Mobility
 Metric scale of mechanical
components. (dialyzer and
pump)
 Metric scale of electrical
components
 AC to DC
• Nickel Metal Hydride
• Lithium Ion
• Smart Batteries
 Design a filtration subsystem
• Ceramic
• Ion Exchange
• Nano filters
• Deionization
• Distillation
Ergonomic
 Simplify operating
system(Automated and
manual)
 Indicate installation unites
with clear figures and
numbers corresponding to
attachment points
 Simplify User manual
 24/7 technical support
Concept Design & Product Development
Concept Generation & Selection

13. Concept Design & Product Development
System-level Design
• Define product architecture.
• Breakdown product into subsystems
and components.
• Initiate a design of major components.
• Adjust industrial design.
• System level design also helped us
initiate a geometric layout of the
product, functional description of
each of the product subsystem, and
initiate a process flow diagram for
final assembly process.
Ion
Exchange
Filter Unit
Nano
Cross
Flow
Filtration

14. Top View
Detail Design

15. Detail Design
Ion
Exchange
Filter Unit
Nano
Cross
Flow
Filtration
Air Trap

16. Concept Design & Product Development
Detail Design
• Define the complete specification of the geometry, materials, and tolerances of all
the unique parts in the product.
• Identify all the standard parts to be purchased from supplier.
• Process plan will be established and tooling is designed for each part to be
invented within the production system.
• A control documentation will be made to describe the geometry of each part and its
production tooling.

17. DIALO-mini
By ReNeual

18. DIALO-mini
By ReNeual

19. X-ray Angle View
DIALO-mini
By ReNeual

20. DIALO-mini
By ReNeual
Operation System
Screen Monitor
Artery Hose Line
Device Logo
(Registered)
Vein Hose Line

21. DIALO-mini
Mechanism

22. Chia-Yi Liu

23. WHERE ARE WE HEADED?
Our mission and goal
- More mobility
- Higher life quality

24. http://www.niddk.nih.gov/
Dialysis
patient
s
Kidney
transpla
nt
The ESRD population in the US is
660,000
468,000 are dialysis patients

25. WHERE ARE WE HEADED?
Targeting our customer
Living in remote area
Inflexible schedule
HOW DO WE GET THERE
Distributing Channel
Selling strategy
Promotion

28. PREVALENCE OF TREATED ESRD BY COUNTRY
http://www.usrds.org/

29. GROWTH STRATEGY

30. GROWTH PLAN
Year 1-4 Year 5-8 Year 9-
Keep growing
Exit strategy
Founders input $749k
as initial investment
Seeking for angel
investor
Will need extra $1.6
M to continue
operations before we
start to commercialize
our product
Obtain a stable
US market
Try to get into
Chinese and Asia
market

31. EXIT STRATEGY
Keep growing
Acquisition with Baxter

32. DIALO-MINI BY RENEUAL

34. APPENDIX 1-INCOME STATEMENT
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Operating Revenue $0 $0 $0 $0 $217,000 $816,463 $3,000,500 $11,026,836 $28,945,445 $60,785,435
Price per unit $0.00 $0.00 $0.00 $0.00 $2,170.00 $2,332.75 $2,449.39 $2,571.86 $2,700.45 $2,835.47
Number of units sold 0 0 0 0 100 350 1225 4288 10719 21438
Operating Expenses $140,000 $127,620 $130,296 $135,030 $207,880 $306,918 $650,063 $1,866,257 $4,474,334 $8,926,702
Variable cost per unit 250 254 258 261 265 269 273 277 282 286
Fixed cost per unit 60 60 61 61 62 62 63 63 64 65
Cost of goods sold per unit 310 314 318 323 327 332 336 341 346 351
Cost of goods sold $0 $0 $0 $0 $32,716 $116,062 $411,737 $1,461,351 $3,704,781 $7,513,845
Gross profit $0 $0 $0 $0 $184,284 $700,401 $2,588,763 $9,565,485 $25,240,664 $53,271,591
Gross profit margin N/A N/A N/A N/A 84.9% 85.8% 86.3% 86.7% 87.2% 87.6%
Depreciation $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000
Royalties 0 $0 $0 $0 $4,340 $16,329 $60,010 $220,537 $578,909 $1,215,709
Royalty % of sales 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0%
Selling costs $0 $0 $0 $0 $35,000 $35,850 $36,725 $37,624 $38,550 $39,504
Research and development $75,000 $61,200 $62,424 $65,672 $64,946 $66,245 $67,570 $70,273 $73,083 $76,007
Administrative $65,000 $66,420 $67,872 $69,358 $70,878 $72,432 $74,022 $76,472 $79,010 $81,638
Operating Profit (EBIT) -$147,000 -$134,620 -$137,296 -$142,030 $2,120 $502,545 $2,343,437 $9,153,579 $24,464,111 $51,851,733
EBIT margin 0.00% 0.00% 0.00% 0.00% 0.98% 61.55% 78.10% 83.01% 84.52% 85.30%
Interest expense $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125
Income Before Taxes -$187,125 -$174,745 -$177,421 -$182,155 -$38,005 $462,420 $2,303,312 $9,113,454 $24,423,986 $51,811,608
Income taxes $0 $0 $0 $0 $0 $23,121 $115,166 $455,673 $3,663,598 $10,362,322
Net Income from Operations -$187,125 -$174,745 -$177,421 -$182,155 -$38,005 $439,299 $2,188,146 $8,657,782 $20,760,388 $41,449,287
Net income from operations margin 0.00% 0.00% 0.00% 0.00% 0.00% 53.81% 72.93% 78.52% 71.72% 68.19%
Non-recurring events $650,000 $500,000 $0 $0 $0 $0 $0 $0 $0 $0
Grants $650,000 $500,000 $0 $0 $0 $0 $0 $0 $0 $0
Total Net Income $462,875 $325,255 -$177,421 -$182,155 -$38,005 $439,299 $2,188,146 $8,657,782 $20,760,388 $41,449,287

35. APPENDIX 2-BALANCE SHEET
2016 Beginning 2016 Ending 2017 2018 2019 2020 2021 2022 2023 2024 2025
Assets
Current assets $5,350,000 $5,569,750 $5,734,260 $5,393,417 $5,043,106 $4,801,153 $5,032,800 $7,009,505 $15,449,793 $35,986,412 $77,205,425
Cash $5,350,000 $5,569,750 $5,734,260 $5,393,417 $5,043,106 $4,801,153 $5,032,800 $7,009,505 $15,449,793 $35,986,412 $77,205,425
Long-term assets 0 63000 56000 49000 42000 35000 28000 21000 14000 7000 0
Lab & manufacturing
equipment 0 $70,000 $70,000 $70,000 $70,000 $70,000 $70,000 $70,000 $70,000 $70,000 $70,000
Accumulated
depreciation $7,000 $14,000 $21,000 $28,000 $35,000 $42,000 $49,000 $56,000 $63,000 $70,000
Net lab &
manufacturing
equipment $63,000 $56,000 $49,000 $42,000 $35,000 $28,000 $21,000 $14,000 $7,000 $0
Total Assets $5,350,000 $5,632,750 $5,790,260 $5,442,417 $5,085,106 $4,836,153 $5,060,800 $7,030,505 $15,463,793 $35,993,412 $77,205,425
Liabilities
Long-term debt $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $0
Note payable $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 0
Total Liabilities $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $1,605,000 $0
Stockholders' Equity
Common stock $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000 $3,745,000
Retained earnings -$187,125 -$361,870 -$539,291 -$721,447 -$759,451 -$320,153 $1,867,993 $10,525,775 $31,286,163 $72,735,450
Total Stockholder's
Equity $3,745,000 $3,557,875 $3,383,130 $3,205,709 $3,023,553 $2,985,549 $3,424,847 $5,612,993 $14,270,775 $35,031,163 $76,480,450
Total Liabilities &
Stockholders' Equity $5,350,000 $5,162,875 $4,988,130 $4,810,709 $4,628,553 $4,590,549 $5,029,847 $7,217,993 $15,875,775 $36,636,163 $76,480,450
(Funding shortfall)/excess funding (+) ($469,875) ($802,130) ($631,709) ($456,553) ($245,605) ($30,953) $187,488 $411,982 $642,751 ($724,975)

36. APPENDIX 3-CASH FLOW
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Sources of Cash $5,819,875 $332,255 ($170,421) ($175,155) ($31,005) $446,299 $2,195,146 $8,664,782 $20,767,388 $41,456,287
Funds from Angel
investors $3,745,000 0 0 0 0 0 0 0 $0 $0
Proceeds from bank loan $1,605,000 0 0 0 0 0 0 0 $0 $0
Grant $650,000 500000 0 0 0 0 0 0 $0 $0
Net income ($187,125) ($174,745) ($177,421) ($182,155) ($38,005) $439,299 $2,188,146 $8,657,782 $20,760,388 $41,449,287
Add: depreciation $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000 $7,000
Adjusted cash receipts ($180,125) ($167,745) ($170,421) ($175,155) ($31,005) $446,299 $2,195,146 $8,664,782 $20,767,388 $41,456,287
Uses of Cash $250,125 $167,745 $170,421 $175,155 $210,948 $214,652 $218,441 $224,494 $230,769 $237,274
Lab & manufacturing equipment $70,000 $0 $0 $0 $0 $0 $0 $0 $0 $0
Marketing $0 $0 $0 $0 $35,000 $35,850 $36,725 $37,624 $38,550 $39,504
Research and development $75,000 $61,200 $62,424 $65,672 $64,946 $66,245 $67,570 $70,273 $73,083 $76,007
Administrative $65,000 $66,420 $67,872 $69,358 $70,878 $72,432 $74,022 $76,472 $79,010 $81,638
Interest paid $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125 $40,125
Repayment of bank loan $0 $0 $0 $0 $0 $0 $0 $0 $0 $1,605,000
Royalties $0 $0 $0 $0 $4,340 $16,329 $60,010 $220,537 $578,909 $1,215,709
Beginning cash balance 0 $5,569,750 $5,734,260 $5,393,417 $5,043,106 $4,801,153 $5,032,800 $7,009,505 $15,449,793 $35,986,412
Sources - uses of cash $5,569,750 $164,510 ($340,843) ($350,311) ($241,953) $231,647 $1,976,705 $8,440,288 $20,536,620 $41,219,013
Ending cash balance $5,569,750 $5,734,260 $5,393,417 $5,043,106 $4,801,153 $5,032,800 $7,009,505 $15,449,793 $35,986,412 $77,205,425

37. APPENDIX 4
Total funding need $5,350,000 ASSUMPTION
Equity % ASSUMPTION 70% $3,745,000
Debt % ASSUMPTION 30% $1,605,000
Angel A 20% $749,000
Angel B 50% $1,872,500
Angel C 30% $1,123,500
Bank Loan
Term 10 years
Interest 2.5% payable annually
Principal $1,605,000
Yearly interest $40,125
Per unit basis
Price $2,170
Variable Costs $250
Outsourced raw materials $200
Labor conversion cost $50
Fixed Cost $60
Factory overhead $20
Marketing $25
Distribution $15
Total Cost $310
Markup 600%
Contribution per unit $1,860
Contribution margin 85.71%